EvolutionaryScale
EvolutionaryScale, founded in 2023, develops frontier AI models for biology, including its flagship product, ESM3.
Secondary Market Price
How EvolutionaryScale Measures Up
To help you manage your EvolutionaryScale equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Seed Stage
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of EvolutionaryScale's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future EvolutionaryScale Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for EvolutionaryScale's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
EvolutionaryScale is a research services company that develops artificial intelligence models for biology. The company produces AI models for proteins and genomes, including its ESM3 and EMSC models, which are used in scientific research and applications. Current activities include a collaboration with NVIDIA AI and the Arc Institute to simulate evolutionary processes and create novel proteins. The company is also sponsoring The Align Foundation's 2025 Protein Engineering Tournament, providing its models to help design enzymes for plastic degradation. Founded in 2023, the team behind the company has been active in the field for nearly a decade. In July 2024, EvolutionaryScale secured $142 million in a seed funding round with investors such as Nat Friedman and Lux Capital.
A significant recent development for the company occurred in 2024 when its team joined Biohub, a scientific community supported by the Chan Zuckerberg Initiative, to accelerate biomedical discovery. This collaboration aims to build predictive models of life and combine AI with experimental biology. The company's future plans include developing AI-powered tools and datasets, with stated goals of simulating virtual cells and a virtual immune system. The overarching vision is to enable the systematic engineering of biology to accelerate scientific discovery and the design of new treatments for diseases.
- Nat Friedman
- Daniel Gross
- Lux Capital
- Amazon Web Services (AWS)
- NVentures
- Co-Founder, Alexander Rives
- Co-Founder, Tom Secru
- Co-Founder, Sal Candido
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is EvolutionaryScale worth joining?
Deciding whether to join a startup like EvolutionaryScale involves weighing many factors, including the potential value of its equity compensation. Tools like Prospect can help you model the potential outcomes of your equity, providing data-driven insights to inform your career decisions.
What should I do with my EvolutionaryScale stock?
The best strategy for your EvolutionaryScale stock depends on your personal financial situation, risk tolerance, and goals. Using a platform like Prospect can help you create customized strategies for exercising options and selling shares to optimize your financial outcome.
Can you sell EvolutionaryScale stock?
As EvolutionaryScale is a private company, selling stock is typically only possible during specific liquidity events, such as a tender offer or on a secondary market. Prospect offers tender offer tools and access to secondary market data to help you navigate these opportunities and decide how much to sell.
How can I find the value of my EvolutionaryScale stock?
Valuing stock in a private company like EvolutionaryScale is complex, as there is no public market price. Prospect uses proprietary predictive models, trained on data similar to what VCs use, to help you forecast the potential future value of your shares.
What is EvolutionaryScale's equity worth?
The true worth of EvolutionaryScale's equity is uncertain until a liquidity event like an IPO or acquisition occurs. However, you can estimate its potential value using forecasting tools like those offered by Prospect, which analyze various data points to project a range of outcomes.
What is EvolutionaryScale's stock ticker symbol?
Since EvolutionaryScale is a private company, it is not traded on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are only assigned to companies once they complete an Initial Public Offering (IPO).
Can I buy or sell EvolutionaryScale stock?
As an employee, you can "buy" stock by exercising your options, and you can sell it during company-approved liquidity events or on secondary markets. Prospect provides customized strategies for timing your option exercises and sales to minimize taxes and maximize returns.
What is the criteria to buy or invest in EvolutionaryScale stock?
Investing in a private company like EvolutionaryScale is typically restricted to employees receiving equity compensation or accredited investors participating in funding rounds. If you are an employee, platforms like Prospect can help you understand and manage the equity you've been granted.
